This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Creative BioMart
product type :
antibody
product name :
Anti-FCGR2A monoclonal antibody, clone GVO-3 [FITC]
catalog :
DCABH-3050
quantity :
50 Tests
clonality :
monoclonal
host :
mouse
conjugate :
FITC
clone name :
GVO-3
reactivity :
human
application :
flow cytometry
product information
Cat :
DCABH-3050
Product Name :
Anti-FCGR2A monoclonal antibody, clone GVO-3 [FITC]
Brand :
Creative Diagnostics
Abbr :
Anti-CD32 MAb, FITC-Conjugated
Host animal :
Mouse
Clone :
GVO-3
Official Symbol :
FCGR2A
Clonality :
Monoclonal
Application :
FC
Target :
FCGR2A
Species Reactivity :
Human
Conjugate :
FITC
Antibody Type :
Primary Antibodies
Immunogen :
Burkitt lymphoma cell line (called “Kobayashi”)
Alternative Names :
FCGR2A; Fc fragment of IgG, low affinity IIa, receptor (CD32); Fc fragment of IgG, low affinity IIa, receptor for (CD32) , FCG2, FCGR2, FCGR2A1; low affinity immunoglobulin gamma Fc region receptor II-a; CD32; CD32A; CDw32; IGFR2; Immunoglobulin G Fc rece
UniProt ID :
P12318
Antibody Isotype :
IgG2b
Size :
50 Tests
Storage :
Store at +4°C.
company information
Creative BioMart
Creative BioMart provides quality recombinant proteins, diagnostic antibodies and antigens, diagnostic enzymes and pharmaceutical enzymes to the research community of biology, clinical research, molecular diagnostics and biopharmaceutical drug development.
We are offering more than 3,000 recombinant proteins, peptides and antibodies. All the products are rigorously tested to meet the most demanding research needs. At the same time, lowest prices in the industry are always guaranteed.
Also, in order to leverage our core competencies and resources, Creative BioMart has formed a large number of corporate partnerships and academic collaborations for product development and distribution. We welcome potential partners and distributors to explore business relationships with Creative BioMart.
questions and comments